drugset / Trial / NCT00037700

Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis

NCT00037700

Phase 2 Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of anakinra (IL-1 ra) and pegsunercept (PEG sTNF-RI) when they are used together in improving the signs and symptoms of rheumatoid arthritis. The study will also evaluate the safety of the combination treatment and its effect on slowing down bone and joint destruction due to rheumatoid arthritis. The results will be compared to the effect when only 1 single medication (anakinra or pegsunercept) is used.

Timeline

Start
2001-05
Primary completion
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic
Subject Pegsunercept Protein / enzyme biologic

Indications